Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Shares Outstanding (Weighted Average): 2022-2025

Historic Shares Outstanding (Weighted Average) for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $74.5 million.

  • Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) rose 19.12% to $74.5 million in Q3 2025 from the same period last year, while for Mar 2025 it was $68.1 million, marking a year-over-year increase of 38.94%. This contributed to the annual value of $64.3 million for FY2024, which is 31.03% up from last year.
  • According to the latest figures from Q3 2025, Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) is $74.5 million, which was down 3.37% from $77.1 million recorded in Q2 2025.
  • Corvus Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $77.1 million during Q2 2025, with a 5-year trough of $46.6 million in Q1 2022.
  • For the 3-year period, Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $59.0 million, with its median value being $62.6 million (2024).
  • Data for Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY soared of 38.94% (in 2025) over the last 5 years.
  • Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $46.6 million in 2022, then climbed by 5.34% to $49.0 million in 2023, then surged by 31.03% to $64.3 million in 2024, then increased by 19.12% to $74.5 million in 2025.
  • Its last three reported values are $74.5 million in Q3 2025, $77.1 million for Q2 2025, and $68.1 million during Q1 2025.